Allogene Therapeutics Inc (NAS:ALLO)
$ 2.14 -0.05 (-2.28%) Market Cap: 459.18 Mil Enterprise Value: 269.53 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

Allogene Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 04:30PM GMT
Release Date Price: $25.53 (-2.33%)
Matthew Thomas Holt
JP Morgan Chase & Co, Research Division - Analyst

Okay. Good morning, everyone. My name is Matthew Holt, and I'm part of the JPMorgan Equity Research Biotech Team here. It is my pleasure to introduce our next presenting company, Allogene Therapeutics. Presenting today for Allogene is the CEO and Co-Founder, David Chang. And please note that following the presentation, we're going to have a breakout in the Olympic Room, which is down the hall to the left. So with that, I'll turn it over to David.

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thank you, Matt, and Happy New Year. It's great to kick off 2020, updating our investors and supporters about what Allogene has been doing and what it intends to do throughout the year.

Much of what we have done over the past 2 years is really laying down the foundation. And starting to move with our pipelines, as we prepare for 2020 and beyond. And hopefully, through the presentation, you'll be convinced about how we see the future, the way that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot